265 related articles for article (PubMed ID: 18849560)
21. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis.
Kardaun SH; Jonkman MF
Acta Derm Venereol; 2007; 87(2):144-8. PubMed ID: 17340021
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Gueudry J; Roujeau JC; Binaghi M; Soubrane G; Muraine M
Arch Dermatol; 2009 Feb; 145(2):157-62. PubMed ID: 19221260
[TBL] [Abstract][Full Text] [Related]
23. Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients.
Saito N; Yoshioka N; Abe R; Qiao H; Fujita Y; Hoshina D; Suto A; Kase S; Kitaichi N; Ozaki M; Shimizu H
J Allergy Clin Immunol; 2013 Feb; 131(2):434-41.e1-9. PubMed ID: 23111236
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of treatments and deceased cases of severe adverse drug reactions--analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis].
Yamane Y; Aihara M; Tatewaki S; Matsukura S; Kanbara T; Yamakawa Y; Ikezawa Z
Arerugi; 2009 May; 58(5):537-47. PubMed ID: 19487835
[TBL] [Abstract][Full Text] [Related]
25. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
Sane SP; Bhatt AD
J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
[TBL] [Abstract][Full Text] [Related]
26. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis.
Stella M; Clemente A; Bollero D; Risso D; Dalmasso P
Burns; 2007 Jun; 33(4):452-9. PubMed ID: 17475410
[TBL] [Abstract][Full Text] [Related]
27. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
28. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies.
Lee HY; Dunant A; Sekula P; Mockenhaupt M; Wolkenstein P; Valeyrie-Allanore L; Naldi L; Halevy S; Roujeau JC
Br J Dermatol; 2012 Sep; 167(3):555-62. PubMed ID: 22639874
[TBL] [Abstract][Full Text] [Related]
29. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
Br J Dermatol; 2006 Feb; 154(2):319-24. PubMed ID: 16433803
[TBL] [Abstract][Full Text] [Related]
30. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
Finkelstein Y; Soon GS; Acuna P; George M; Pope E; Ito S; Shear NH; Koren G; Shannon MW; Garcia-Bournissen F
Pediatrics; 2011 Oct; 128(4):723-8. PubMed ID: 21890829
[TBL] [Abstract][Full Text] [Related]
31. Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a university hospital.
Ferrándiz-Pulido C; García-Fernández D; Domínguez-Sampedro P; García-Patos V
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1153-9. PubMed ID: 21198948
[TBL] [Abstract][Full Text] [Related]
32. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective.
Mockenhaupt M; Kelly JP; Kaufman D; Stern RS;
J Rheumatol; 2003 Oct; 30(10):2234-40. PubMed ID: 14528522
[TBL] [Abstract][Full Text] [Related]
33. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Lipowicz S; Sekula P; Ingen-Housz-Oro S; Liss Y; Sassolas B; Dunant A; Roujeau JC; Mockenhaupt M
Br J Dermatol; 2013 Apr; 168(4):726-32. PubMed ID: 23413807
[TBL] [Abstract][Full Text] [Related]
34. [Stevens-Johnson syndrome and toxic epidermal necrolysis: a 15-year retrospective study].
Moniz P; Casal D; Mavioso C; Castro JV; Almeida MA
Acta Med Port; 2011; 24(1):59-70. PubMed ID: 21672443
[TBL] [Abstract][Full Text] [Related]
35. Association of combined IL-13/IL-4R signaling pathway gene polymorphism with Stevens-Johnson syndrome accompanied by ocular surface complications.
Ueta M; Sotozono C; Inatomi T; Kojima K; Hamuro J; Kinoshita S
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1809-13. PubMed ID: 18263811
[TBL] [Abstract][Full Text] [Related]
36. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study.
Gau SS; Chao PF; Lin YJ; Chang CJ; Gau CS
J Clin Psychopharmacol; 2008 Oct; 28(5):509-17. PubMed ID: 18794645
[TBL] [Abstract][Full Text] [Related]
37. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 10-year experience in a burns unit.
Houschyar KS; Tapking C; Borrelli MR; Nietzschmann I; Puladi B; Ooms M; Rein S; Houschyar M; Duscher D; Maan ZN; Reumuth G; Branski LK; Modabber A; Kluwig D; Schmitt L; Philipp-Dormston WG; Yazdi AS; Siemers F
J Wound Care; 2021 Jun; 30(6):492-496. PubMed ID: 34121430
[TBL] [Abstract][Full Text] [Related]
38. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.
Valeyrie-Allanore L; Wolkenstein P; Brochard L; Ortonne N; Maître B; Revuz J; Bagot M; Roujeau JC
Br J Dermatol; 2010 Oct; 163(4):847-53. PubMed ID: 20500799
[TBL] [Abstract][Full Text] [Related]
39. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
Abe R
J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
[TBL] [Abstract][Full Text] [Related]
40. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Morel E; Escamochero S; Cabañas R; Díaz R; Fiandor A; Bellón T
J Allergy Clin Immunol; 2010 Mar; 125(3):703-10, 710.e1-710.e8. PubMed ID: 20132973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
